Abnormal regulation of the LDL-R and HMG CoA reductase genes in subjects with familial hypercholesterolemia with the "French Canadian Mutation"

Atherosclerosis

Volumn 124, Issue 1, 1996, Pages 103-117

  Yu, Lu ^a   Qiu, Shiqiang ^a,c   Genest, Jacques ^a,b,c  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MONTREAL HEART INSTITUTE   (Canada)

Author keywords

3 Hydroxy 3 methylglutaryl coenzyme A reductase; Familial hypercholesterolemia; Low density lipoprotein receptor; Ribonuclease protection assay

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; RIBONUCLEASE; SIMVASTATIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SEQUENCE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE CONTROL; HUMAN; IMMUNOBLOTTING; MALE; PATHOGENESIS; PRIORITY JOURNAL;

ANTICHOLESTEREMIC AGENTS; CANADA; CELLS, CULTURED; ENZYME INDUCTION; ENZYME INHIBITORS; ETHNIC GROUPS; FEMALE; FIBROBLASTS; FRANCE; GENE EXPRESSION REGULATION; HAPLOIDY; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS, LDL; LOVASTATIN; MALE; PREVALENCE; RECEPTORS, LDL; RNA, MESSENGER; SEQUENCE DELETION; TRANSCRIPTION, GENETIC; TREATMENT FAILURE;

EID: 0029941121     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(96)05828-5     Document Type: Article

References (44)

1. Goldstein JL, Brown MS. Familial hypercholesterolemia. In: Scriver CR et al. (eds). The metabolic basis of inherited disease. 6th edn. New York: McGraw Hill, 1989;1215-1250.
2. Davignon J, Roy M, Dufour R, Roederer G. Familial hypercholesterolemia. In: Steiner G, Shafrir E. (eds). Primary hyperlipidemias. New York: McGraw Hill, 1991;201-215.
3. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Human Mutat 1992;1:445-466.
4. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-47.
5. Leitersdorf E, Tobin EJ, Davignon J, Hobbs HH. Common low-density lipoprotein receptor mutations in the French Canadian population. J Clin Invest 1990;85:1014-1023.
6. Hobbs HH, Brown MS, Russell DW, Davignon J, Goldstein JL. Deletion in the gene for the low-density-lipoprotein receptor in a majority of French Canadians with familial hypercholesterolemia. N Engl J Med 1987;317:734-737.
7. Moorjani S, Roy M, Gagne C, Davignon J, Brun D, Toussaint M, Lambert M, Campeau L, Blaichman S, Lupien P. Homozygous familial hypercholesterolemia among French Canadians in Quebec Province. Arteriosclerosis 1989;9:211-216.
8. Moorjani S, Roy M, Torres A, Betard C, Gagne C, Lambert M, Brun D, Davignon J, Lupien P. Mutations of low-density-lipoprotein-receptor gene, variations in plasma cholesterol, and expression of coronary heart disease in homozygous familial hypercholesterolaemia. Lancet 1993;341:1303-1306.
9. Karayan L, Qiu S, Betard C, Dufour R, Roederer G, Minnich A, Davignon J, Genest J Jr. Response to HMG CoA reductase inhibitors in heterozygous familial hypercholesterolemia due to the 10-kb deletion ("French Canadian Mutation") of the LDL receptor gene. Arterioscler Thromb 1994;14:1258-1263.
10. Ma YH, Betard C, Roy M, Davignon J, Kessling AM. Identification of a second "French Canadian" LDL receptor gene deletion and development of a rapid method to detect both deletions. Clin Genet 1989;36:219-228.
11. McNicoll S, Latour Y, Rondeau C, Bouthillier D, Davignon J, Genest J Jr. Cardiovascular risk factors and lipoprotein profile in French Canadians with premature CAD: impact of the NCEP II guidelines. Can J Cardiol 1995;11:109-116.
12. Goldstein JL, Basu SK, Brown MS. Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. Methods Enzymol 1983;98:241-260.
13. Azrolan N, Breslow JL. A solution hybridization/RNase protection assay with riboprobes to determine absolute levels of apoB, A-I, and E mRNA in human hepatoma cell lines. J Lipid Res 1990;31:1141-1146.
14. Cuthbert JA, Lipsky PE. Differential regulation of the expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase, synthase, and low density lipoprotein receptor genes. J Lipid Res 1992;33:1157-1163.
15. Le Cras TD, Gherardi E, Bowyer DE. A sensitive RNase protection assay for the quantitation of the mRNAs for the LDL receptor and HMG CoA reductase in human total RNA. Effects of treatments on cells in culture designed to up- and down-regulate expression of the LDL receptor. Atherosclerosis 1991;90:81-90.
16. Molowa DT, Cimis GM. Co-ordinate regulation of low-density-lipoprotein receptor and 3-hydroxy-3-methylglutaryl-CoA reductase and synthase gene expression in HepG2 cells. Biochem J 1989;260:731-736.
17. Pape ME, Melchior GW, Marotti KR. mRNA quantitation by a simple and sensitive RNAse protection assay. Genet Anal Tech Appl 1991;8(7):206-213.
18. Srivastava RA, Pfleger BA, Schonfeld G. Expression of LDL receptor, apolipoprotein B, apolipoprotein A-I and apolipoprotein A-IV mRNA in various mouse organs as determined by a novel RNA-excess solution hybridization assay. Biochim Biophys Acta 1991;1090:95-101.
19. Innerarity TL, Weisgraber KH, Arnold KS, Mahley RW, Krauss RM, Vega GL, Grundy SM. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci USA 1987;84:6919-6923.
20. Knight BL, Patel DD, Gavigan SJ, Soutar AK. Low-density-lipoprotein-receptor mRNA content of fibroblasts from normal and familial hypercholesterolaemic subjects. Eur J Biochem 1988;178:555-561.
21. Tam SP, Brissette L, Ramharack R, Deeley RG. Differences between the regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and low density lipoprotein receptor in human hepatoma cells and fibroblasts reside primarily at the translational and post-translational levels. J Biol Chem 1991;266:16764-16773.
22. Rudling M. Hepatic mRNA levels for the LDL receptor and HMG-CoA reductase show coordinate regulation in vivo. J Lipid Res 1992;33:493-501.
23. Powell EE, Kroon PA. Low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in human mononuclear leukocytes is regulated coordinately and parallels gene expression in human liver. J Clin Invest 1994;93:2168-2174.
24. Qin W, Infante J, Wang SR, Infante R. Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvaslatin and ciprofibrate in Hep G2, human and rat hepatocytes. Biochim Biophys Acta 1992;1127:57-66.
25. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-430.
26. Betard C, Kessling AM, Roy M, Chamberland A, Lussier-Cancan S, Davignon J. Molecular genetic evidence for a founder effect in familial hypercholesterolemia among French Canadians. Hum Genet 1992;88:529-536.
27. Davignon J, Montigny M, Dufour R. HMG-CoA reductase inhibitors: a look back and a look ahead. Can J Cardiol 1992;8:843-864.
28. Ma PT, Gil G, Sudhof TC, Bilheimer DW, Goldstein JL, Brown MS. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci USA 1986;83:8370-8374.
29. Peffley DM. Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase synthesis in Syrian hamster C100 cells by mevinolin, 25-hydroxycholesterol, and mevinalonate: the role of post-transcriptional control. Som Cell Mol Genet 1992;18:19-32.
30. Sviridov DD, Safonova IG, Pavlov MY, Kosykh VA, Podrez EA, Antonov AS, Fuki IV, Repin VS. Inhibition of cholesterol synthesis by lovastatin tested on six human cell types in vitro. Lipids 1990;25:177-179.
31. Wang X, Sato R, Brown MS, Hua X, Goldstein JL. SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis. Cell 1994;77:53-62.
32. Yokoyama C, Wang X, Briggs MR, Admon A, Wu J, Hua X, Goldstein JL, Brown MS. SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell 1993;75:187-197.
33. Gasic GP. Basic-helix-loop-helix transcription factor and sterol sensor in a single membrane-bound molecule. Cell 1994;77:17-19.
34. Breslow JL, Spaulding DR, Lux SE, Levy RI, Lees RS. Homozygous familial hypercholesterolemia. A possible biochemical explanation of clinical heterogeneity. N Engl J Med 1975;293:900-903.
35. Schuster H, Rauh G, Kormann B, Hepp T, Humphries S, Keller C, Wolfram G, Zollner N. Familial defective apolipoprotein B-100. Comparison with familial hypercholesterolemia in 18 cases detected in Munich. Arteriosclerosis 1990;10:577-581.
36. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990;264:3007-3012.
37. Thiery J, Walli AK, Janning G, Seidel D. Low-density lipoprotein plasmaphaeresis with and without lovastatin in the treatment of the homozygous form of familial hypercholesterolaemia. Eur J Pediatr 1990;149:716-721.
38. Koga N, Iwata Y. Pathological and angiographic regression of coronary atherosclerosis by LDL-apheresis in a patient with familial hypercholesterolemia. Atherosclerosis 1991;90:9-21.
39. Nishimura S, Yamaguchi H. L-CAPS group investigators. Regression of coronary atherosclerosis by intensive lipid-lowering therapy with combined LDL-apheresis and drugs in familial hypercholesterolemia: Japan LDL Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS) (abstr.). Circulation 1994;2745.
40. Grossman M, Raper SE, Kozarsky K, Stein EA, Engelhardt JF, Muller D, Lupien PJ, Wilson JM. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet 1994;6:335-341.
41. Weatherall D. Heroic Gene Surgery. Nat Genet 1994;6:325-326.
42. Marshall E. Gene therapy's growing pains. Science 1995;269:1050-1055.
43. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease: II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973;52:1544-1568.
44. Genest J Jr., Martin-Munley SR, McNamara JR, Ordovas JM, Jenner J, Meyers RH, Silberman SR, Wilson PWF, Salem DN, Schaefer EJ. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992;85:2025-2033.